Mammoth Biosciences
Jacqueline Laurel is an experienced research professional with a strong background in cell and molecular biology. Currently serving as a Senior Research Associate at Mammoth Biosciences since March 2022, Jacqueline previously held roles at CODA Biotherapeutics and protocols.io, progressing from Research Associate I to II. Additionally, Jacqueline contributed to research initiatives as an intern at the Frankel Lab at the University of California, San Francisco. Educational credentials include a Bachelor of Science in Cell/Cellular and Molecular Biology from San Francisco State University and a Biotechnology Certificate from City College of San Francisco.
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.